Clinical Trials · NCT07272837
Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
- Phase
- N/A
- Recruitment status
- Recruiting
- Sponsor
- University of Alberta
- Enrollment
- 50
- Start date
- May 2026
- Locations
- 1 site, Canada
- Primary endpoint
- Changes in skeletal and cardiac muscle mass